Orgenesis (ORGS) Competitors

$0.60 +0.20 (+48.75%)

As of 09:44 AM Eastern

ORGS vs. CELZ, PMCB, LNAI, OBSV, and GNPX

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Creative Medical Technology (CELZ), Nuvilex (PMCB), Lunai Bioworks (LNAI), ObsEva (OBSV), and Genprex (GNPX). These companies are all part of the "pharmaceutical products" industry.

How does Orgenesis compare to Creative Medical Technology?

Orgenesis (NASDAQ:ORGS) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

: 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Orgenesis has a beta of 3.07, meaning that its share price is 207% more volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
: Creative Medical Technology has lower revenue, but higher earnings than Orgenesis. Creative Medical Technology is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
Creative Medical Technology $10K 825.10 -$5.99M -$2.59 N/A
: In the previous week, Creative Medical Technology had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled Creative Medical Technology'saverage media sentiment score.
Company Overall Sentiment
Orgenesis Neutral
Creative Medical Technology Neutral
: Creative Medical Technology has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Creative Medical Technology's return on equity.
Company Net Margins Return on Equity Return on Assets
Orgenesis -3,827.81% N/A -130.18%
Creative Medical Technology N/A -85.62% -82.36%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Creative Medical Technology
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A
Creative Medical Technology	$10K	825.10	-$5.99M	-$2.59	N/A

Company	Overall Sentiment
Orgenesis	Neutral
Creative Medical Technology	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Creative Medical Technology	N/A	-85.62%	-82.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Creative Medical Technology beats Orgenesis on 7 of the 12 factors compared between the two stocks.

How does Orgenesis compare to Nuvilex?

Orgenesis (NASDAQ:ORGS) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Nuvilex
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.
Company Overall Sentiment
Orgenesis Neutral
Nuvilex Neutral
: Orgenesis has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
: Nuvilex has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Nuvilex's return on equity of 2.13% beat Orgenesis' return on equity.
Company Net Margins Return on Equity Return on Assets
Orgenesis -3,827.81% N/A -130.18%
Nuvilex N/A 2.13% 1.69%
: 22.6% of Orgenesis shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Nuvilex has lower revenue, but higher earnings than Orgenesis. Nuvilex is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
Nuvilex N/A N/A $30.66M -$1.12 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Orgenesis	Neutral
Nuvilex	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Nuvilex	N/A	2.13%	1.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

Nuvilex beats Orgenesis on 8 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Lunai Bioworks?

Orgenesis (NASDAQ:ORGS) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Lunai Bioworks
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Lunai Bioworks had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Lunai Bioworks and 0 mentions for Orgenesis. Lunai Bioworks' average media sentiment score of 0.27 beat Orgenesis' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the news media.
Company Overall Sentiment
Orgenesis Neutral
Lunai Bioworks Neutral
: Orgenesis has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
: Lunai Bioworks has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Lunai Bioworks' return on equity.
Company Net Margins Return on Equity Return on Assets
Orgenesis -3,827.81% N/A -130.18%
Lunai Bioworks N/A -1,243.45% -360.31%
: 22.6% of Orgenesis shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Orgenesis has higher revenue and earnings than Lunai Bioworks. Orgenesis is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
Lunai Bioworks N/A N/A -$178.01M $0.05 6.24

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Orgenesis	Neutral
Lunai Bioworks	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Lunai Bioworks	N/A	-1,243.45%	-360.31%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	$0.05	6.24

Summary

Orgenesis and Lunai Bioworks tied by winning 6 of the 12 factors compared between the two stocks.

How does Orgenesis compare to ObsEva?

Orgenesis (NASDAQ:ORGS) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

: Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
ObsEva N/A N/A -$58.38M -$0.92 N/A
: Orgenesis has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.
: ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity.
Company Net Margins Return on Equity Return on Assets
Orgenesis -3,827.81% N/A -130.18%
ObsEva N/A -416.36% -92.01%
: In the previous week, Orgenesis' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.
Company Overall Sentiment
Orgenesis Neutral
ObsEva Neutral
: 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
ObsEva	N/A	-416.36%	-92.01%

Company	Overall Sentiment
Orgenesis	Neutral
ObsEva	Neutral

Summary

Orgenesis and ObsEva tied by winning 5 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Genprex?

Genprex (NASDAQ:GNPX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

: Genprex has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Genprex's return on equity.
Company Net Margins Return on Equity Return on Assets
Genprex N/A -464.05% -275.54%
Orgenesis -3,827.81% N/A -130.18%
: In the previous week, Genprex had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Genprex and 0 mentions for Orgenesis. Genprex's average media sentiment score of 0.08 beat Orgenesis' score of 0.00 indicating that Genprex is being referred to more favorably in the media.
Company Overall Sentiment
Genprex Neutral
Orgenesis Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Orgenesis
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Genprex has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genprex N/A N/A -$16.23M -$26.50 N/A
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
: 14.1% of Genprex shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 0.4% of Genprex shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-464.05%	-275.54%
Orgenesis	-3,827.81%	N/A	-130.18%

Company	Overall Sentiment
Genprex	Neutral
Orgenesis	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A

Summary

Orgenesis beats Genprex on 7 of the 12 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGS vs. The Competition

Export

Metric	Orgenesis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.08M	$889.45M	$6.24B	$11.86B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	-0.05	1.71	29.04	28.48
Price / Sales	4.65	120.50	477.10	60.43
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	-0.09	7.60	9.67	6.67
Net Income	-$55.36M	-$4.80M	$3.55B	$332.64M
7 Day Performance	-17.36%	-0.05%	1.70%	2.01%
1 Month Performance	-0.83%	5.50%	5.62%	9.19%
1 Year Performance	-74.73%	30.96%	34.42%	39.59%

Orgenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGS Orgenesis	N/A	$0.60 +48.8%	N/A	N/A	$3.08M	$662K	N/A	150	Gap Down
CELZ Creative Medical Technology	0.1224 of 5 stars	$2.22 -0.4%	N/A	N/A	$8.21M	$6K	N/A	5	Upcoming Earnings Gap Down
PMCB Nuvilex	0.7199 of 5 stars	$0.75 -1.3%	N/A	N/A	$8.05M	N/A	N/A	4	Positive News
LNAI Lunai Bioworks	0.5638 of 5 stars	$0.33 -2.1%	N/A	N/A	$8.05M	N/A	6.65	20	News Coverage Gap Down
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orgenesis (ORGS) Competitors

ORGS vs. CELZ, PMCB, LNAI, OBSV, and GNPX

How does Orgenesis compare to Creative Medical Technology?

Summary

How does Orgenesis compare to Nuvilex?

Summary

How does Orgenesis compare to Lunai Bioworks?

Summary

How does Orgenesis compare to ObsEva?

Summary

How does Orgenesis compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orgenesis (ORGS) Competitors

ORGS vs. CELZ, PMCB, LNAI, OBSV, and GNPX

How does Orgenesis compare to Creative Medical Technology?

Summary

How does Orgenesis compare to Nuvilex?

Summary

How does Orgenesis compare to Lunai Bioworks?

Summary

How does Orgenesis compare to ObsEva?

Summary

How does Orgenesis compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools